Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heidi Prather

Dermatology Austin, TX Medical Doctor

NPI 1053630582 CMS profile 1309741

8825 Bee Caves Rd Ste 100, Austin, TX 78746

Open in the dashboard

General payments

$542,988

779 records reported · program years 2019–2025

Research payments

$76

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heidi Prather of Austin, TX is reported in the CMS Open Payments database as having received $542,988 across 779 general payments and $76 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36,862 67
2024 General $122,390 127
2024 Research $76 1
2023 General $92,214 142
2022 General $107,457 189
2021 General $88,705 107
2020 General $40,570 34
2019 General $54,791 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heidi Prather
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Heidi Prather were reported at $36,862. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Heidi Prather Dermatology median Middle half National median
2019 $54,791 $454 $129–$1,240 $163
2020 $40,570 $235 $81–$756 $114
2021 $88,705 $377 $108–$1,108 $132
2022 $107,457 $514 $143–$1,391 $149
2023 $92,214 $607 $159–$1,674 $160
2024 $122,390 $751 $204–$1,903 $164
2025 $36,862 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $405,723 428 payments
  2. AbbVie, Inc. $79,012 180 payments
  3. Allergan Inc. $26,822 91 payments
  4. Merz North America, Inc. $20,746 39 payments
  5. Revance Therapeutics, Inc. $4,986 14 payments
  6. Solta Medical, a division of Bausch Health US, LLC $4,528 4 payments
  7. Aclaris Therapeutics, Inc. $558 6 payments
  8. Amgen Inc. $144 1 payment
  9. Almirall LLC $133 1 payment
  10. Genzyme Corporation $54 2 payments
  11. Other $283 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $363,831 91 payments
  2. Consulting Fee $112,440 31 payments
  3. Travel and Lodging $45,371 189 payments
  4. Food and Beverage $21,075 429 payments
  5. Education $271 39 payments
Products named General payments · program years 2019–2025
  1. BOTOX $43,483 112 payments
  2. Xeomin Dermatology $17,063 17 payments
  3. BOTOX COSMETIC $11,066 29 payments
  4. DAXXIFY $4,758 10 payments
  5. ESKATA $510 2 payments
  6. Xeomin musculoskeletal $418 5 payments
  7. DAXI $229 4 payments
  8. DYSPORT $212 4 payments
  9. DYSPORT $209 4 payments
  10. Otezla $144 1 payment
  11. Other $626 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $76 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Dermatology: 534

Drug cost

$157

Median for Dermatology: $67,151

Branded share of claims

100%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valacyclovir Valacyclovir Hcl Brand 12 $157

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $14,269
$14,269 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $174
$174 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $138
$138 — —
DYSPORT
  • Galderma Laboratories, L.P. $95
$95 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

780 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record